Camp4 Therapeutics (CAMP) Current Deferred Revenue (2024 - 2026)

Camp4 Therapeutics' Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $11.1 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue changed N/A year-over-year to $11.1 million; the TTM figure through Mar 2026 stood at $11.1 million (changed N/A YoY), while the FY2025 annual figure was $9.4 million, up 2338.18% from the prior year.
• Current Deferred Revenue came in at $11.1 million for Q1 2026 at Camp4 Therapeutics, up from $9.4 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $11.1 million in Q1 2026 to a low of $385000.0 in Q4 2024.
• A 3-year average of $5.5 million and a median of $5.2 million in 2024 frame the typical range for Current Deferred Revenue.
• On a YoY basis, Current Deferred Revenue climbed as much as 2338.18% in 2025 and fell as far as 2338.18% in 2025.
• Camp4 Therapeutics' Current Deferred Revenue stood at $385000.0 in 2024, then soared by 2338.18% to $9.4 million in 2025, then climbed by 17.98% to $11.1 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $11.1 million, $9.4 million, and $385000.0 for Q1 2026, Q4 2025, and Q4 2024 respectively.

Peer Comparison